Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
This article was originally published in The Tan Sheet
Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.
You may also be interested in...
Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.
The private labeler lowered its full-year revenue guidance, noting weak cough/cold/flu OTC sales. Perrigo built up excess capacity to take advantage of recalled Johnson & Johnson OTCs, and now is shifting some capacity in response to a Novartis plant shutdown.
Homeopathic firm TheraBiogen plans to roll out products “every six to nine months” to add to its existing lineup of homeopathic remedies for allergy and cold and flu, says CEO Kelly Hickel. The firm also counts on sales growth from a social media campaign to explain what is not in its products as well as what is.